Document Detail

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.
MedLine Citation:
PMID:  21145907     Owner:  NLM     Status:  MEDLINE    
BACKGROUND & AIMS: This study investigated the efficacy and adverse effects of pegylated interferon (Peg-IFN) plus ribavirin therapy in aged patients with chronic hepatitis C (CH-C).
METHODS: A total of 1040 naïve patients with CH-C (genotype 1, n=759; genotype 2, n=281), of whom 240 (23%) over 65 years old (y.o.), were treated with Peg-IFN alfa-2b plus ribavirin and assessed after being classified into five categories, according to age.
RESULTS: The discontinuance rate was higher for patients over 70 y.o. (36%), the most common reason being anemia. In the presence of genotype 1, the SVR rate was similar (42-46%) among patients under 65 y.o. and declined (26-29%) among patients over 65 y.o. For patients over 65 y.o., being male (Odds ratio, OR, 3.5, p=0.035) and EVR (OR, 83.3, p<0.001) were significant factors for SVR, in multivariate analysis. The Peg-IFN dose was related to EVR, and when EVR was attained, 76-86% of patients over 65 y.o. achieved SVR. SVR was not achieved (0/35, 0/38, respectively) if a 1-log decrease and a 2-log decrease were not attained at week 4 and week 8, respectively. In the presence of genotype 2, the SVR rate was similar (70-71%) among patients under 70 y.o. and declined among patients over 70 y.o. (43%).
CONCLUSIONS: Aged patients up to 65 y.o. with genotype 1 and 70 y.o. with genotype 2 can be candidates for Peg-IFN plus ribavirin therapy. The response-guided therapy can be applied for aged patients with genotype 1.
Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Masahide Oshita; Hideki Hagiwara; Eiji Mita; Toshifumi Ito; Hiroyuki Fukui; Yoshiaki Inui; Taizo Hijioka; Masami Inada; Kazuhiro Kaytayama; Shinji Tamura; Harumasa Yoshihara; Atsuo Inoue; Yasuharu Imai; Michio Kato; Takuya Miyagi; Yuichi Yoshida; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Norio Hayashi
Related Documents :
21272987 - Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users.
6266297 - Survival among patients with lung cancer. an epidemiologic study.
21344467 - Reflections on involuntary treatment in the prevention of fatal anorexia nervosa: a rev...
1089507 - Pulmonary function studies in ex-heroin users.
8877257 - Sample size calculations for within-patient comparisons with a binary or survival endpo...
8073807 - Methotrexate in psoriatic polyarthritis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-12-09
Journal Detail:
Title:  Journal of hepatology     Volume:  54     ISSN:  1600-0641     ISO Abbreviation:  J. Hepatol.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-18     Completed Date:  2011-07-15     Revised Date:  2012-08-24    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  604-11     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antiviral Agents / administration & dosage*,  adverse effects
Cohort Studies
Drug Therapy, Combination
Hepacivirus / classification,  genetics
Hepatitis C, Chronic / drug therapy*,  virology
Interferon-alpha / administration & dosage*,  adverse effects
Middle Aged
Polyethylene Glycols / administration & dosage*,  adverse effects
RNA, Viral / blood
Recombinant Proteins
Retrospective Studies
Ribavirin / administration & dosage*,  adverse effects
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/RNA, Viral; 0/Recombinant Proteins; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 99210-65-8/interferon alfa-2b
Comment In:
J Hepatol. 2011 Apr;54(4):597-8   [PMID:  21167854 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Induction of NEIL1 and NEIL2 DNA glycosylases in aniline-induced splenic toxicity.
Next Document:  Overexpression of PaParp encoding the poly(ADP-ribose) polymerase of Podospora anserina affects orga...